BIAKŌS™ ANTIMICROBIAL SKIN & WOUND CLEANSER

BIAKŌS™ ANTIMICROBIAL SKIN & WOUND CLEANSER works synergistically to cleanse and remove microbes from the wound bed to help eliminate planktonic, immature and mature biofilms.

Buy Now Sales Brochure Product Insert

BIAKŌS™ Works Synergistically

The patented technology and ingredients in BIAKŌS™ work to:

Eliminate...

Planktonic, immature and mature biofilms.

Attack...

Gram-negative bacteria, Gram-positive bacteria, fungi, viruses and spores

Support...

Normal wound-healing pH.

Remove...

Odor producing microbes.

Create...

A safe environment conducive to wound healing.

Safely Disrupt Biofilm Microbes

BIAKŌS™ ANTIMICROBIAL SKIN & WOUND CLEANSER is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms, from wounds. Such as:

• Stage I-IV Pressure Ulcers • First- and second-degree burns • Diabetic foot ulcers • Grafted and donor sites • Post-surgical wounds

Ingredients in BIAKŌS™ ANTIMICROBIAL SKIN & WOUND CLEANSER

*PHMB

Poloxamer 407

Ingredients in BIAKOS Antimicrobial Skin & Wound Cleanser

*Synergistic Ingedients

*Vicinal Diols

*EDTAs

Learn More about the Synergistic Ingredients

BIAKŌS™ Is Effective Against*

Gram-positive bacteria

Clostridium difficile

Enterococcus faecalis

Methicillin Resistant Staphylococcus aureus (MRSA)

Staphylococcus aureus

Staphylococcus epidermidis

Vancomycin Resistant Enterococcus faecalis (VREF)

Gram-negative bacteria

Acinetobacter baumannii

Carbapenum Resistant Escherichia coli (CRE)

Enterobacter cloacae

Escherichia coli

Klebsiella pneumoniae

Proteus mirabilis

Pseudomonas aeruginosa

Serratia marcescens

Fungi

Candida albicans

Candida auris

Trichosporin asahii

Viruses

Human Coronavirus

SARS‐CoV‐2

Spores

Bacillus cereus

Clostridium difficile

*Kill rate testing in solution; Data on file

Keep Up With the Latest Developments in Surgical and Wound Care Technology

Most Recent Press Releases

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2020 Results

March 31, 2021

Sanara MedTech Inc. Announces Closing of $31.6 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 18, 2021

Sanara MedTech Inc. Announces Pricing of Public Offering

February 12, 2021

All Press Releases

Get In Touch